人福医药：咪达唑仑注射液获德国上市许可批准

Core Viewpoint - The company has received marketing authorization for midazolam injection from the German Federal Institute for Drugs and Medical Devices (BfArM), indicating a significant regulatory achievement that could enhance its market presence in Europe [1] Group 1: Regulatory Approval - The company's subsidiary, Yichang Renfu Pharmaceutical Co., Ltd., has been granted marketing authorization for midazolam injection by BfArM [1] - The approved indications for midazolam injection include: 1) conscious sedation before, during, and after diagnostic or therapeutic procedures, with or without local anesthesia; 2) preoperative medication for adult anesthesia induction, anesthesia induction, and use in combination with other anesthetics as a sedative; preoperative medication for pediatric anesthesia induction; 3) sedation in the Intensive Care Unit (ICU) [1]